Novartis Outsources Singapore Eye-Care Sales as October's Data and Deals Stack Up

Novartis shifts Singapore ophthalmology sales to DKSH as investors await remibrutinib MS data on Oct 23 and Q3 results on Oct 27.

Novartis has handed the commercial reins for its ophthalmology portfolio in Singapore to DKSH, the Swiss market-expansion specialist, in a move that reshapes how the drugmaker reaches patients across Southeast Asia. Announced Thursday, the partnership tasks DKSH with marketing, sales, and credit-and-collections management for the relevant eye-care medicines on the ground.

The arrangement is the latest in a series of operational adjustments at the Basel-based group, which is simultaneously steering toward a dense cluster of clinical and financial milestones this month.

Shares Edge Higher, Still Below Peak

Novartis stock finished Friday's session at EUR 127.90, a gain of 0.7% on the day. The equity remains roughly 11% shy of its 52-week high of EUR 144.30. Intraday trading during the month has seen the shares fetch as much as EUR 128.10, up 0.9% at one point, though the broader picture still leaves the stock in discount territory relative to its yearly peak.

Neurology Takes Center Stage

Investor attention is converging on the company's multiple sclerosis pipeline. Novartis confirmed it will present 46 scientific abstracts spanning its MS portfolio at the MSToronto2026 specialist congress. The headline event lands on October 23, when late-stage Phase III data from the REMODEL-1 and REMODEL-2 trials of remibrutinib are due to be unveiled. Fresh findings on Kesimpta in pediatric multiple sclerosis are also on the agenda, and the company has signaled a virtual investor event dedicated to the remibrutinib program.

The Bruton's tyrosine kinase inhibitor has already notched wins elsewhere. Under the brand name Rhapsido, it became the first FDA-approved therapy for adults with symptomatic dermographism whose symptoms are not adequately controlled by H1 antihistamines. In the pivotal Phase III trial, 29.3% of patients on the drug achieved complete resolution of wheals at 12 weeks, compared with 14.0% on placebo — a result that extends remibrutinib's reach beyond chronic spontaneous urticaria.

Not every readout has gone Novartis's way. According to media reports, the company halted the Phase III RELIEVE study in generalized myasthenia gravis after a prespecified futility analysis indicated the efficacy targets would likely be missed. No safety concerns were cited, and other development programs for the compound were unaffected.

RNA Bet Anchors the Pipeline

Earlier in the month, Novartis moved to shore up its nucleic-acid capabilities. On October 2, it struck an agreement with Abogen Biosciences securing worldwide exclusive rights to the candidate ABO2203, alongside options on additional programs from the RNA platform.

The structure of the deal is substantial. Abogen receives a USD 575 million upfront payment, with milestone payments of up to roughly USD 7.2 billion if all options are exercised and every development goal is met. Revenue-linked royalties could follow. Reuters pegs the total potential value of the collaboration at around USD 7.8 billion. For Novartis, the tie-up is a deliberate play to deepen its access to novel RNA therapies and broaden the portfolio with innovative approaches early — a hedge against future patent expirations.

Countdown to the Quarterly Print

The next hard numbers arrive on October 27, when Novartis reports third-quarter and nine-month results for 2026. Investors are looking for dependable visibility into operating growth, and the report will serve as a gauge of how well the company's medium-term expansion strategy is holding up. Between the MS data drop, the RNA deal, and the quarterly update, the coming weeks amount to a decisive stretch for the Swiss pharma giant.